Literature DB >> 11472874

The long-term response to levodopa in dopa-responsive dystonia.

W J Hwang1, D B Calne, J K Tsui, R de la Fuente-Fernández.   

Abstract

We report the long-term response to levodopa in 20 patients with dopa-responsive dystonia (DRD). We found an inverse correlation between the daily dose of levodopa and duration of treatment (r=-0.59, P<0.01). Mild dyskinesias were present in 20% of our patients. Dyskinetic patients were on a higher dose of levodopa than non-dyskinetics. Dyskinesias responded to a reduction in levodopa, with no deterioration in motor function. We propose that the dopamine turnover might decrease with time, which would lead to a decrease in the requirement for levodopa and the occurrence of dyskinesias late in the course of DRD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472874     DOI: 10.1016/s1353-8020(00)00084-5

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  15 in total

Review 1.  Treatment of dystonia.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  Segawa syndrome due to mutation Q89X in the GCH1 gene: a possible founder effect in Córdoba (southern Spain).

Authors:  Eduardo López-Laso; Juan José Ochoa-Sepúlveda; Juan José Ochoa-Amor; Enrique Bescansa-Heredero; Rafael Camino-León; Francisco Javier Gascón-Jiménez; Maria Elena Mateos-González; Juan Luis Pérez-Navero; José Ignacio Lao-Villadóniga; Aida Ormazabal; Rafael Artuch; Katrin Beyer
Journal:  J Neurol       Date:  2009-06-16       Impact factor: 4.849

Review 3.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

4.  Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.

Authors:  Samuel J Rose; Porter Harrast; Christine Donsante; Xueliang Fan; Valerie Joers; Malú G Tansey; H A Jinnah; Ellen J Hess
Journal:  Mov Disord       Date:  2017-09-26       Impact factor: 10.338

Review 5.  Monoamine neurotransmitter disorders--clinical advances and future perspectives.

Authors:  Joanne Ng; Apostolos Papandreou; Simon J Heales; Manju A Kurian
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

6.  Diagnosis and treatment of neurotransmitter disorders.

Authors:  Phillip L Pearl; Thomas R Hartka; Jacob Taylor
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.598

7.  Dyskinesias as a limiting factor in the treatment of Segawa disease.

Authors:  Eduardo López-Laso; Katrin Beyer; Thomas Opladen; Rafael Artuch; Rachel Saunders-Pullman
Journal:  Pediatr Neurol       Date:  2012-06       Impact factor: 3.372

8.  Childhood dystonias.

Authors:  Samer D Tabbal
Journal:  Curr Treat Options Neurol       Date:  2015-03       Impact factor: 3.598

9.  Current and future medical treatment in primary dystonia.

Authors:  Cathérine C S Delnooz; Bart P C van de Warrenburg
Journal:  Ther Adv Neurol Disord       Date:  2012-07       Impact factor: 6.570

10.  Dopa-responsive Dystonia in Children.

Authors:  Jonathan W. Mink
Journal:  Curr Treat Options Neurol       Date:  2003-07       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.